NCT06310941

Brief Summary

Multicenter, randomized open label clinical trial to evaluate IEM and HS as concomitant therapy for respiratory tract infection in patients under artificial ventilation in the ICU. Lung infection is a serious complication that may occur during hospital stay and may need artificial respiration or even develop during artificial ventilation for other causes. Current specific treatment consists of intravenous antibiotics. The current study evaluated whether aspiration and drainage of infected sputum helps curing this severe complication and whether nebulized HS has additional benefits, like loosening of secretions, eradicating bacteria or reducing inflammation.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
20mo left

Started Jan 2026

Typical duration for not_applicable

Geographic Reach
1 country

8 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress17%
Jan 2026Dec 2027

First Submitted

Initial submission to the registry

February 27, 2024

Completed
17 days until next milestone

First Posted

Study publicly available on registry

March 15, 2024

Completed
1.8 years until next milestone

Study Start

First participant enrolled

January 1, 2026

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2027

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2027

Last Updated

March 26, 2025

Status Verified

March 1, 2025

Enrollment Period

1.5 years

First QC Date

February 27, 2024

Last Update Submit

March 21, 2025

Conditions

Keywords

mechanical insufflation-exsufflationcough assist devicehypertonic salinenosocomial respiratory tract infectionhospital-acquired pneumoniatracheobronchitisventilator-associated pneumonianebulization

Outcome Measures

Primary Outcomes (3)

  • Median SOFA score increase >2 points on day 4

    Increase in organ dysfunction score from baseline to day 4 after randomization.

    inclusion to day 4 after randomization

  • Median respiratory support-free days increase at day 28

    28 minus duration in days on high-flow nasal cannula + invasive ventilation.

    Inclusion to day 28 after randomization

  • Percentage of subjects surviving/dying day 28

    crude mortality on day 28 after randomization

    Inclusion to day 28 after randomization

Secondary Outcomes (4)

  • Subjects with bacterial eradication in respiratory samples at day 4 after randomization

    Day 3 to 5 after randomization

  • Subjects with bacterial eradication in respiratory samples at end of systemic antibiotic therapy

    7 and 14 days after randomization

  • Median Length of ICU stay

    ICU admission to discharge or death in days

  • Median antibiotic-free days at 28 days

    from study inclusion to day 28

Study Arms (3)

Standard of Care

ACTIVE COMPARATOR

Standard of care: Systemic antibiotic therapy according to local protocol and at the discretion of the attending intensivist.

Other: Standard of Care

Mechanical insufflation-exsufflation with hypertonic saline/hyaluronic acid comination

EXPERIMENTAL

Systemic antibiotic therapy choice according to local protocol and at the discretion of the attending intensivist plus Mechanical insufflation-exsufflation (MI-E sessión tid during the first 48 hours, followed by MI-E if secretions are present or suspected; recommended settings +50 cmH2O/-50 cmH2O) with simultaneous nebulization of hypertonic saline (7%) with hyaluronic acid (0.1%).

Device: Mechanical insufflation-exsufflationOther: Hypertonic saline with hyaluronic acid

Mechanical insufflation-exsufflation

EXPERIMENTAL

Systemic antibiotic therapy choice according to local protocol and at the discretion of the attending intensivist plus Mechanical insufflation-exsufflation (MI-E sessión tid during the first 48 hours, followed by MI-E if secretions are present or suspected; recommended settings +50 cmH2O/-50 cmH2O)

Device: Mechanical insufflation-exsufflation

Interventions

Combined use of mechanical insufflation-exsufflation with nebulized hypertonic saline in intubated patients with nosocomial respiratory tract infection

Also known as: Cough Assist
Mechanical insufflation-exsufflationMechanical insufflation-exsufflation with hypertonic saline/hyaluronic acid comination

systemic antibiotic therapy and catheter suctioning of secretions as recommended by guidelines

Also known as: Routine care of respiratory tract infection
Standard of Care

Commercially available combination of 7% hypertonic saline with 0.1% hyaluronic acid given as nebulization during the MI-E session

Also known as: (Hyaneb-TM)
Mechanical insufflation-exsufflation with hypertonic saline/hyaluronic acid comination

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Signed informed consent
  • Nosocomial pneumonia (vHAP or VAP) or nosocomial tracheobronchitis
  • Intubated with a cuffed endotracheal tube or tracheostomy cannula.

You may not qualify if:

  • Ominous prognosis
  • Frank hemoptisis
  • Barotrauma (pneumothorax or pneumomediastinum)
  • Bronchospasm (patients on bronchodilators for previous bronchospasm may be included
  • Unstable thoracic cage
  • Suspected unmonitored intracraneal hypertension

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Hospital Vall d´Hebrón.

Barcelona, Barcelona, Spain

Location

Hospital Nuestra Señora de la Candelaria.

Santa Cruz de Tenerife, Las Palmas, Spain

Location

Hospital Clinico San Carlos

Madrid, Madrid, 28040, Spain

Location

Hospital Clínico San Carlos

Madrid, Madrid, 28040, Spain

Location

Hospital de la Princesa

Madrid, Madrid, Spain

Location

Hospital Doce de Octubre

Madrid, Madrid, Spain

Location

Hospital Álvaro Cunqueiro.

Vigo, Pontevedra, Spain

Location

Virgen de la Salud

Toledo, Toledo, Spain

Location

Related Publications (4)

  • Sanchez-Garcia M, Alvarez-Gonzalez M, Domingo-Marin S, Pino-Ramirez AD, Martinez-Sagasti F, Gonzalez-Arenas P, Cardenal-Sanchez C, Velasco-Lopez E, Nunez-Reiz A. Comparison of Mechanical Insufflation-Exsufflation and Hypertonic Saline and Hyaluronic Acid With Conventional Open Catheter Suctioning in Intubated Patients. Respir Care. 2024 Apr 22;69(5):575-585. doi: 10.4187/respcare.11566.

    PMID: 38307525BACKGROUND
  • Ferreira de Camillis ML, Savi A, Goulart Rosa R, Figueiredo M, Wickert R, Borges LGA, Galant L, Teixeira C. Effects of Mechanical Insufflation-Exsufflation on Airway Mucus Clearance Among Mechanically Ventilated ICU Subjects. Respir Care. 2018 Dec;63(12):1471-1477. doi: 10.4187/respcare.06253. Epub 2018 Jul 17.

    PMID: 30018175BACKGROUND
  • Knudtzen FC, Sprehn M, Vestbo J, Johansen IS. Mechanical insufflation/exsufflation compared with standard of care in patients with pneumonia: A randomised controlled trial. Eur J Anaesthesiol. 2020 Nov;37(11):1077-1080. doi: 10.1097/EJA.0000000000001209. No abstract available.

    PMID: 33027229BACKGROUND
  • Sanchez-Garcia M, Santos P, Rodriguez-Trigo G, Martinez-Sagasti F, Farina-Gonzalez T, Del Pino-Ramirez A, Cardenal-Sanchez C, Busto-Gonzalez B, Requesens-Solera M, Nieto-Cabrera M, Romero-Romero F, Nunez-Reiz A. Preliminary experience on the safety and tolerability of mechanical "insufflation-exsufflation" in subjects with artificial airway. Intensive Care Med Exp. 2018 Apr 3;6(1):8. doi: 10.1186/s40635-018-0173-6.

    PMID: 29616357BACKGROUND

MeSH Terms

Conditions

Cross InfectionHealthcare-Associated PneumoniaPneumonia, Ventilator-Associated

Interventions

Standard of CareSaline Solution, HypertonicHyaluronic Acid

Condition Hierarchy (Ancestors)

InfectionsIatrogenic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsPneumoniaRespiratory Tract InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and EvaluationHypertonic SolutionsSolutionsPharmaceutical PreparationsGlycosaminoglycansPolysaccharidesCarbohydrates

Study Officials

  • Belén De la Hera Hernanz, PhD

    Hospial Clinico San Carlos

    STUDY DIRECTOR

Central Study Contacts

Miguel Sánchez Garcia, MD. PhD.

CONTACT

Belén De la Hera Hernanz, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: multicenter, randomized, open label
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Emeritus Critical Care Department

Study Record Dates

First Submitted

February 27, 2024

First Posted

March 15, 2024

Study Start

January 1, 2026

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

December 30, 2027

Last Updated

March 26, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will share

Anonymyzed data sheet of all subjects and variables for a pre-specified analysis plan.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
After study publication
Access Criteria
Anonymyzed data sheet of all subjects and variables for a pre-specified analysis plan.

Locations